Heartware (HTWR) Bullish Stance Reiterated at Credit Suisse After Industry Conversations

Credit Suisse analyst B. Nudell reiterated an Outperform rating and $90 price target on Heartware Int'l (NASDAQ: HTWR) saying they are more bullish on MVAD following conversations with LVAD Engineer/Management.

"Our conclusion after these discussions is that MVAD is likely to improve on HVAD's clot generation & vWF disruption profile as well as on the HVAD's vulnerability to clot ingestion," the analyst said.

For an analyst ratings summary and ratings history on Heartware Int'l click here. For more ratings news on Heartware Int'l click here.

Shares of Heartware Int'l closed at $86.76 yesterday.

You May Also Be Interested In

• META to capture largest share of users, SNAP to benefit from ad budget shifts - Canaccord Genuity weighs in on TikTok ban
• CACI International (CACI) PT Raised to $440 at Stifel
• Amazon.com (AMZN) PT Raised to $215 at UBS